Vaccines are an especially risky proposition for pharmaceutical manufacturers since the costs are higher than for other types of drugs and demand could drop drastically once a crisis is over.
By
MIT study explores the key factors behind patient outcomes in clinical trials evaluating new treatments for non-small-cell lung cancer.
By
The studies describe new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines.
By
MIT Sloan and CSAIL researchers apply artificial intelligence techniques to one of the largest datasets of clinical trial outcomes to handicap the drug and device approval process
By
The MIT Laboratory for Financial Engineering (LFE) and Informa Pharma Intelligence announced a new initiative, Project ALPHA (Analytics for Life-sciences Professionals and Healthcare Advocates).
Researchers launched an in-house Data Science and Artificial Intelligence (DSAI) challenge to beat MIT’s machine-learning models for predicting clinical trial outcomes. The results are now available.
By
The COVID-19 pandemic damages the U.S. and the world economy and puts policymakers in an unfamiliar dilemma. Non-pharmaceutical interventions (NPIs) such as social distancing slow the spread of [...]
By
The MIT Sloan School of Management announces a major gift from alumnus Bennett (Ben) W. Golub to support the MIT Center for Finance and Policy.
By
In an article in The Hill, Bob Pozen explores how the recently enacted Cares Act has tax provisions that favor wealthy investors and large companies. There is proposed legislation now in Congress to [...]
By
MIT panel talks fiscal, global, and legal consequences of the government’s near-default. When MIT Sloan professor Deborah Lucas scheduled a panel discussion titled “U.S. Fiscal Crisis: Causes and Consequences,” the government was shut down, no compromise seemed imminent, and what the state of affair...
